Evaxion Biotech A/S (NASDAQ:EVAX) Shares Scheduled to Reverse Split on Monday, January 13th

Evaxion Biotech A/S (NASDAQ:EVAX)’s stock is scheduled to reverse split before the market opens on Monday, January 13th. The 1-5 reverse split was announced on Monday, December 30th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, January 10th.

Evaxion Biotech A/S Price Performance

EVAX opened at $0.89 on Thursday. The company has a 50 day moving average of $1.47 and a two-hundred day moving average of $2.43. Evaxion Biotech A/S has a 52-week low of $0.83 and a 52-week high of $13.61. The company has a quick ratio of 2.80, a current ratio of 1.00 and a debt-to-equity ratio of 7.99. The company has a market cap of $5.22 million, a P/E ratio of -3.07 and a beta of -0.39.

Evaxion Biotech A/S (NASDAQ:EVAX) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.08. The business had revenue of $3.02 million for the quarter, compared to analysts’ expectations of $0.19 million. On average, analysts expect that Evaxion Biotech A/S will post -0.15 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $14.00 target price on shares of Evaxion Biotech A/S in a report on Friday, November 1st.

Institutional Investors Weigh In On Evaxion Biotech A/S

A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. Invst LLC acquired a new stake in Evaxion Biotech A/S (NASDAQ:EVAX) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 54,000 shares of the company’s stock, valued at approximately $156,000. Invst LLC owned about 1.00% of Evaxion Biotech A/S at the end of the most recent reporting period. 11.04% of the stock is owned by institutional investors and hedge funds.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.